RecruitingOverweight , ObesityAdults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Eligible age
18–75 yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with semaglutide.
Sponsor: Alveus Therapeutics, Inc.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07837973 · last updated 2026-09-24